Jagsonpal Historical Balance Sheet

JAGSNPHARM

636.65 9.80 1.52%

Trend analysis of Jagsonpal Pharmaceuticals Limited balance sheet accounts such as Other Current Liabilities of 78.7 M or Total Current Liabilities of 361.4 M provides information on Jagsonpal Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Jagsonpal Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Jagsonpal Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Jagsonpal Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jagsonpal Pharmaceuticals is a good buy for the upcoming year.

Jagsonpal Pharmaceuticals Inventory

247.28 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Jagsonpal Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Jagsonpal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Jagsonpal Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jagsonpal Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jagsonpal currently owns. An asset can also be divided into two categories, current and non-current.

Jagsonpal Pharmaceuticals Balance Sheet Chart

As of now, Jagsonpal Pharmaceuticals' Cash is increasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Non Currrent Assets Other is estimated to increase to about 40.1 M, while Total Assets are projected to decrease to under 1.7 B.

Total Current Liabilities Net Debt Retained Earnings Non Current Assets Total

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Jagsonpal Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Jagsonpal Pharmaceuticals Limited are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Most accounts from Jagsonpal Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Jagsonpal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2023	2024 (projected)
Short and Long Term Debt Total	60.0M	89.4M	165.5M
Total Assets	1.7B	2.2B	1.7B

Short Long Term Debt Total Total Assets

Jagsonpal Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Current Deferred Revenue	Good Will	Other Liab
Total Assets		-0.23	0.34	-0.07	0.91	-0.33	-0.08	0.78	-0.1	-0.37	0.07	0.77	-0.47	0.2	-0.14	-0.78	0.51	-0.06	-0.22	0.9	-0.31	0.17	0.09	-0.31	-0.78	-0.29
Short Long Term Debt Total	-0.23		-0.62	0.55	-0.58	0.87	0.9	-0.44	-0.57	0.61	0.27	-0.49	0.82	-0.08	0.34	0.12	-0.43	-0.2	0.94	-0.47	0.94	-0.07	-0.61	-0.25	0.3	0.72
Other Current Liab	0.34	-0.62		0.11	0.5	-0.42	-0.57	0.47	0.42	-0.31	-0.24	0.4	-0.46	0.05	-0.74	-0.17	0.32	0.05	-0.51	0.4	-0.45	0.05	0.32	0.36	-0.33	-0.55
Total Current Liabilities	-0.07	0.55	0.11		-0.35	0.67	0.34	-0.18	-0.04	0.69	0.18	-0.38	0.49	-0.07	-0.56	0.16	-0.29	-0.32	0.69	-0.41	0.7	-0.05	0.03	-0.07	0.36	0.29
Total Stockholder Equity	0.91	-0.58	0.5	-0.35		-0.63	-0.39	0.79	0.08	-0.59	-0.02	0.82	-0.69	0.16	-0.2	-0.67	0.58	0.03	-0.59	0.96	-0.63	0.12	0.24	-0.18	-0.77	-0.48
Property Plant And Equipment Net	-0.33	0.87	-0.42	0.67	-0.63		0.74	-0.65	-0.42	0.86	0.17	-0.72	0.89	-0.42	0.09	0.22	-0.68	-0.13	0.93	-0.58	0.95	-0.41	-0.46	0.04	0.55	0.79
Net Debt	-0.08	0.9	-0.57	0.34	-0.39	0.74		-0.3	-0.87	0.39	0.36	-0.33	0.78	-0.03	0.41	0.1	-0.39	-0.16	0.75	-0.26	0.8	-0.02	-0.81	-0.39	0.05	0.81
Retained Earnings	0.78	-0.44	0.47	-0.18	0.79	-0.65	-0.3		0.07	-0.65	0.02	0.91	-0.68	0.58	-0.2	-0.64	0.69	-0.09	-0.49	0.76	-0.56	0.56	0.23	-0.38	-0.85	-0.57
Cash	-0.1	-0.57	0.42	-0.04	0.08	-0.42	-0.87	0.07		-0.09	-0.38	0.09	-0.54	-0.03	-0.38	-0.04	0.27	0.11	-0.37	-0.02	-0.45	-0.03	0.79	0.52	0.22	-0.75
Non Current Assets Total	-0.37	0.61	-0.31	0.69	-0.59	0.86	0.39	-0.65	-0.09		-0.08	-0.78	0.68	-0.54	-0.14	0.24	-0.62	-0.17	0.78	-0.66	0.76	-0.52	-0.02	0.07	0.74	0.65
Non Currrent Assets Other	0.07	0.27	-0.24	0.18	-0.02	0.17	0.36	0.02	-0.38	-0.08		-0.04	0.22	0.05	-0.03	0.27	-0.39	-0.24	0.18	0.08	0.22	0.05	-0.16	-0.25	-0.06	0.13
Cash And Short Term Investments	0.77	-0.49	0.4	-0.38	0.82	-0.72	-0.33	0.91	0.09	-0.78	-0.04		-0.78	0.66	-0.01	-0.71	0.79	-0.02	-0.58	0.8	-0.66	0.64	0.15	-0.23	-0.94	-0.61
Net Receivables	-0.47	0.82	-0.46	0.49	-0.69	0.89	0.78	-0.68	-0.54	0.68	0.22	-0.78		-0.43	0.18	0.46	-0.72	0.08	0.8	-0.59	0.89	-0.41	-0.62	-0.02	0.56	0.83
Common Stock Shares Outstanding	0.2	-0.08	0.05	-0.07	0.16	-0.42	-0.03	0.58	-0.03	-0.54	0.05	0.66	-0.43		0.05	-0.29	0.68	-0.15	-0.25	0.14	-0.3	1.0	-0.02	-0.36	-0.61	-0.36
Non Current Liabilities Total	-0.14	0.34	-0.74	-0.56	-0.2	0.09	0.41	-0.2	-0.38	-0.14	-0.03	-0.01	0.18	0.05		-0.13	-0.07	0.23	0.18	-0.04	0.11	0.05	-0.5	-0.09	-0.1	0.29
Inventory	-0.78	0.12	-0.17	0.16	-0.67	0.22	0.1	-0.64	-0.04	0.24	0.27	-0.71	0.46	-0.29	-0.13		-0.55	0.11	0.12	-0.63	0.26	-0.27	-0.02	0.16	0.68	0.21
Other Current Assets	0.51	-0.43	0.32	-0.29	0.58	-0.68	-0.39	0.69	0.27	-0.62	-0.39	0.79	-0.72	0.68	-0.07	-0.55		-0.02	-0.53	0.52	-0.56	0.65	0.2	-0.21	-0.64	-0.61
Other Stockholder Equity	-0.06	-0.2	0.05	-0.32	0.03	-0.13	-0.16	-0.09	0.11	-0.17	-0.24	-0.02	0.08	-0.15	0.23	0.11	-0.02		-0.15	0.08	-0.19	-0.14	-0.05	0.38	-0.01	-0.11
Total Liab	-0.22	0.94	-0.51	0.69	-0.59	0.93	0.75	-0.49	-0.37	0.78	0.18	-0.58	0.8	-0.25	0.18	0.12	-0.53	-0.15		-0.51	0.96	-0.23	-0.39	-0.09	0.44	0.65
Total Current Assets	0.9	-0.47	0.4	-0.41	0.96	-0.58	-0.26	0.76	-0.02	-0.66	0.08	0.8	-0.59	0.14	-0.04	-0.63	0.52	0.08	-0.51		-0.55	0.1	0.08	-0.17	-0.8	-0.45
Short Term Debt	-0.31	0.94	-0.45	0.7	-0.63	0.95	0.8	-0.56	-0.45	0.76	0.22	-0.66	0.89	-0.3	0.11	0.26	-0.56	-0.19	0.96	-0.55		-0.29	-0.51	-0.09	0.5	0.72
Common Stock	0.17	-0.07	0.05	-0.05	0.12	-0.41	-0.02	0.56	-0.03	-0.52	0.05	0.64	-0.41	1.0	0.05	-0.27	0.65	-0.14	-0.23	0.1	-0.29		-0.01	-0.35	-0.58	-0.35
Accounts Payable	0.09	-0.61	0.32	0.03	0.24	-0.46	-0.81	0.23	0.79	-0.02	-0.16	0.15	-0.62	-0.02	-0.5	-0.02	0.2	-0.05	-0.39	0.08	-0.51	-0.01		0.1	0.15	-0.64
Current Deferred Revenue	-0.31	-0.25	0.36	-0.07	-0.18	0.04	-0.39	-0.38	0.52	0.07	-0.25	-0.23	-0.02	-0.36	-0.09	0.16	-0.21	0.38	-0.09	-0.17	-0.09	-0.35	0.1		0.28	-0.28
Good Will	-0.78	0.3	-0.33	0.36	-0.77	0.55	0.05	-0.85	0.22	0.74	-0.06	-0.94	0.56	-0.61	-0.1	0.68	-0.64	-0.01	0.44	-0.8	0.5	-0.58	0.15	0.28		0.36
Other Liab	-0.29	0.72	-0.55	0.29	-0.48	0.79	0.81	-0.57	-0.75	0.65	0.13	-0.61	0.83	-0.36	0.29	0.21	-0.61	-0.11	0.65	-0.45	0.72	-0.35	-0.64	-0.28	0.36

Click cells to compare fundamentals

Jagsonpal Pharmaceuticals Account Relationship Matchups

Jagsonpal Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.5B	1.6B	1.7B	1.9B	2.2B	1.7B
Short Long Term Debt Total	37.9M	46.6M	67.9M	60.0M	89.4M	165.5M
Other Current Liab	155.5M	117.4M	4.6M	183.3M	88.5M	78.7M
Total Current Liabilities	328.3M	404.0M	341.6M	275.7M	191.3M	361.4M
Total Stockholder Equity	1.1B	1.2B	1.3B	1.6B	1.9B	1.2B
Property Plant And Equipment Net	239.6M	233.5M	223.7M	242.8M	93.0M	88.4M
Net Debt	(334.1M)	(518.4M)	(251.4M)	(50.5M)	(38.2M)	(36.3M)
Retained Earnings	476.9M	585.9M	675.2M	945.4M	1.0B	1.1B
Cash	380.7M	586.3M	251.4M	110.5M	127.6M	199.6M
Non Current Assets Total	520.4M	437.3M	576.8M	303.9M	178.2M	169.3M
Non Currrent Assets Other	(353.8M)	38.3M	29.2M	27.2M	38.2M	40.1M
Cash And Short Term Investments	380.7M	618.8M	472.8M	1.1B	1.5B	1.6B
Net Receivables	224.5M	126.6M	155.8M	221.1M	109.5M	104.0M
Liabilities And Stockholders Equity	1.5B	1.6B	1.7B	1.9B	2.2B	1.7B
Non Current Liabilities Total	30.9M	18.8M	34.4M	84.8M	105.5M	87.4M
Inventory	293.3M	297.2M	297.4M	206.8M	150.0M	247.3M
Other Current Assets	274.5M	143.6M	80.6M	41.9M	363.2M	381.4M
Total Liab	359.2M	422.7M	376.0M	360.6M	296.8M	350.2M
Total Current Assets	949.1M	1.2B	1.1B	1.6B	2.0B	1.1B
Accumulated Other Comprehensive Income	(337.4M)	1.1B	496.9M	506.5M	588.7M	618.2M
Short Term Debt	64.0M	67.9M	7.5M	7.5M	13.8M	13.1M
Accounts Payable	117.1M	180.5M	185.5M	78.5M	76.0M	96.0M
Current Deferred Revenue	92.1M	137.5M	(7.5M)	81.4M	12.9M	12.3M
Other Liab	30.9M	18.8M	34.4M	32.4M	29.1M	26.0M
Net Tangible Assets	1.1B	1.2B	1.3B	1.6B	1.8B	1.2B
Other Assets	170.1M	82.9M	147.0M	20.3M	23.4M	22.2M
Property Plant Equipment	239.6M	233.5M	223.7M	242.8M	218.5M	258.8M
Cash And Equivalents	398.1M	589.4M	232.3M	110.5M	127.1M	242.0M
Net Invested Capital	1.2B	1.3B	1.3B	1.6B	1.9B	1.5B
Net Working Capital	620.8M	800.8M	766.2M	1.4B	1.8B	1.1B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in Jagsonpal Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jagsonpal Historical Balance Sheet

Jagsonpal Pharmaceuticals Inventory

247.28 Million

About Jagsonpal Balance Sheet Analysis

Jagsonpal Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Net Debt

Retained Earnings

Non Current Assets Total

Jagsonpal Pharmaceuticals balance sheet Correlations

Jagsonpal Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jagsonpal Pharmaceuticals balance sheet Accounts

Also Currently Popular

Other Information on Investing in Jagsonpal Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Total Current Assets	+ 0.96	Total Stockholder Equity
Short Term Debt	+ 0.96	Total Liab
Short Term Debt	+ 0.95	Property Plant And Equipment Net
Total Liab	+ 0.94	Short Long Term Debt Total
Short Term Debt	+ 0.94	Short Long Term Debt Total

Good Will	- 0.94	Cash And Short Term Investments
Cash	- 0.87	Net Debt
Good Will	- 0.85	Retained Earnings
Accounts Payable	- 0.81	Net Debt
Good Will	- 0.8	Total Current Assets
Net Receivables	- 0.78	Cash And Short Term Investments